Ibudilast

A phosphodiesterase inhibitor used in the treatment of neurological disorders

Ibudilast
File:Ibudilast.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Ibudilast is a phosphodiesterase inhibitor that has been investigated for its potential use in treating various neurological disorders. It is known for its anti-inflammatory and neuroprotective properties.

Mechanism of Action

Ibudilast works primarily by inhibiting the activity of phosphodiesterase (PDE) enzymes, particularly PDE-4 and PDE-10. This inhibition leads to an increase in intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which are important secondary messengers in cellular signaling pathways. By modulating these pathways, ibudilast exerts its anti-inflammatory and neuroprotective effects.

Therapeutic Uses

Ibudilast has been studied for its potential benefits in several neurological conditions, including:

Multiple Sclerosis

Ibudilast has shown promise in the treatment of multiple sclerosis (MS), a chronic autoimmune disease that affects the central nervous system. It may help reduce inflammation and slow the progression of the disease.

Neuropathic Pain

The drug has also been investigated for its ability to alleviate neuropathic pain, which is pain caused by damage to the nervous system. Its anti-inflammatory properties may help reduce pain and improve quality of life for patients.

Drug Addiction

Research has explored the use of ibudilast in treating drug addiction, particularly for substances such as methamphetamine and opioids. It may help reduce cravings and withdrawal symptoms.

Side Effects

Common side effects of ibudilast include nausea, headache, and dizziness. More serious side effects are rare but can include liver dysfunction and allergic reactions.

Pharmacokinetics

Ibudilast is administered orally and is well absorbed from the gastrointestinal tract. It is metabolized in the liver and excreted primarily in the urine. The drug has a half-life of approximately 19 hours, allowing for once or twice daily dosing.

Research and Development

Ongoing research is exploring the full potential of ibudilast in various neurological and inflammatory conditions. Clinical trials are being conducted to better understand its efficacy and safety profile.

Related pages

• Phosphodiesterase inhibitor
• Multiple sclerosis
• Neuropathic pain
• Drug addiction

• Ibudilast
  Ibudilast